Nov 5, 2026
Vericel Delivers Its Strongest Beat-And-Raise Of 2026, But Burn Care Spike And A Cautious 2027 Signal Temper The Story
Vericel (NASDAQ: VCEL) exceeded third-quarter earnings and revenue estimates significantly, prompting management to raise full-year revenue and adjusted EBITDA margin guidance. While the company saw strong growth in its MACI product line, a substantial portion of the beat came from an unpredictable spike in its Burn Care franchise. Investors are left with a cautious outlook for 2027, tempering the overall positive news despite improved fundamental performance.
Company relevance
100.00%
Company sentiment
Somewhat-Bullish
Overall sentiment
Somewhat-Bullish
Nov 5, 2026
Vericel Q3 2026 Earnings Call Transcript
Vericel Corporation reported record third-quarter revenue of over $85 million, a 26% increase year-over-year, significantly exceeding guidance and leading to raised full-year revenue guidance of $344-$346 million. The company saw strong performance across its MACI and Burn Care franchises, with MACI achieving record revenue of over $67 million and Burn Care increasing by 52%. Vericel is also preparing for potential international expansion and continued investments in sales force and commercial initiatives, anticipating sustained growth and profitability.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish